Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014204 · ClinicalTrials.gov registry record · NA
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
A NA study, sponsored by Endogenex.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT05014204 is a NA study that has completed, run by Endogenex. The registered enrollment target is 20 participants.
The verdict
NCT05014204, a NA study, has completed, sponsored by Endogenex.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.
Interventions
- DEVICE The Endogenex Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2025-05-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014204
The ClinicalTrials.gov registry entry for NCT05014204 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endogenex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The Endogenex Device is the first listed.
NCT05014204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05014204 about?
NCT05014204 is a clinical study titled "Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes". This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.
What is the current status of trial NCT05014204?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-10-29. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT05014204?
The interventions under investigation include: The Endogenex Device (DEVICE).
Who is sponsoring clinical trial NCT05014204?
This trial is sponsored by Endogenex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.